Compounds and methods of their use
Novel ITK and BTK inhibitors, synthesized through specific reaction schemes, address the limitations of current inhibitors by providing effective treatment for autoimmune diseases and cancers with reduced toxicity and enhanced efficacy.
Patent Information
- Application Number
- PCT/CN2026/096074
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-06-05
- Filing Date
- 2026-05-11
- Publication Date
- 2026-11-19
AI Technical Summary
Current ITK and BTK inhibitors exhibit limited efficacy and high toxicity, necessitating the development of new compounds with improved therapeutic benefits and reduced side effects for treating diseases associated with T- and B-cell activation and dysregulation.
Development of novel compounds, including dual inhibitors of ITK and BTK, formulated as pharmaceutically acceptable salts, which are synthesized through specific reaction schemes, capable of inhibiting both kinases with high specificity and low toxicity.
The compounds effectively inhibit ITK and BTK activity, offering therapeutic benefits in treating autoimmune diseases and cancers with reduced toxicity and improved efficacy, as demonstrated by IC₅₀ values below 500 nM in biochemical assays.
Smart Images

Figure PCTCN2026096074-FTAPPB-I100001 
Figure PCTCN2026096074-FTAPPB-I100002 
Figure PCTCN2026096074-FTAPPB-I100003
Abstract
Description
COMPOUNDS AND METHODS OF THEIR USE
[0001] This application claims priority to PCT International Application PCT / CN2025 / 094145, filed May 12, 2025, and to U.S. Provisional Application 63 / 818,103, filed June 5, 2025, the entireties of which are incorporated herein by reference.1. BACKGROUND
[0002] Protein phosphorylation is a basic and important mechanism for regulating and controlling protein viability and function. The phosphorylation of tyrosine residues is catalyzed by protein tyrosine kinases (PTKs) , of which ninety unique genes have been identified. Yin, Z., et al., “Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease” Cell Death Discovery (2022) 8: 119, 1. Two classes of PTKs exist in cells: transmembrane receptor PTKs and non-receptor PTKs. Examples of non-receptor PTKs include interleukin-2-inducible T-cell kinase (ITK) and Bruton's tyrosine kinase (BTK) . Id.
[0003] Both ITK and BTK are expressed in hematopoietic tissues. ITK is primarily expressed in T cells, natural killer cells, and mast cells, while BTK is expressed in B cells and myeloid cell lineages. Yang, Wen-Chin, et al., “The Role of Tec Protein-tyrosine Kinase in T Cell Signaling” J. Biol. Chem. (1999) 274 (2) : 607-617, 607. Consequently, the inhibition of both proteins has been explored for the treatment of diseases associated with T-and B-cell activation and dysregulation, such as lymphoma and graft-versus-host disease. See, e.g., Braun, L.M., and Zeiser, R., “Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease” Front. Immunol. (2021) 12: 760199, 1.
[0004] For example, the ITK inhibitor soquelitinib, currently in clinical trials, has shown promise in the treatment of patients with relapsed / refractory peripheral T-cell lymphoma (PTCL) . Corvus Pharmaceuticals, “Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed / Refractory Peripheral T-Cell Lymphoma” Press Release issued September 10, 2024. The BTK inhibitors ibrutinib and zanubrutinib have been approved for the treatment of graft-versus-host disease and B-cell malignancies such as chronic lymphocytic leukemia, small lymphocytic lymphoma, macroglobulinemia, mantle cell lymphoma, and follicular lymphoma. See, e.g., Wolska-Washer, A. and Robak, T., “Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions” Front. Oncol. (1023) 13: 1130595.
[0005] Despite the reported efficacy of known ITK and BTK inhibitors, a need remains for new inhibitors with greater efficacy and lower toxicity. See, e.g., Lipsky, A. and Lamanna, N., “Managing toxicities of Bruton tyrosine kinase inhibitors” Hematology Am. Soc. Hematol. Educ. Program (2020) 1: 336-345.2. SUMMARY
[0006] This invention is directed, in part, to compounds useful as kinase inhibitors. Some compounds are inhibitors of interleukin-2-inducible T-cell kinase (ITK) . Some are inhibitors of Bruton's tyrosine kinase (BTK) . Preferred compounds are inhibitors of both ITK and BTK.
[0007] Particular compounds of the invention include compounds of Formula I
[0008] and pharmaceutically acceptable salts thereof, the substituents of which are defined herein.
[0009] This invention also encompasses methods of treating, managing or preventing diseases or conditions associated with ITK or BTK activity, which methods comprise administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound of the invention. Particular methods of the invention include methods of treating, managing or preventing autoimmune diseases or conditions and cancer.
[0010] This invention also encompasses methods of preparing ITK and BTK inhibitors and compounds useful as intermediates in their synthesis.3. DETAILED DESCRIPTION
[0011] This invention is directed to novel inhibitors of ITK and BTK. Preferred compounds are dual inhibitors (i.e., are able to inhibit both ITK and BTK) .
[0012] 3.1. DEFINITIONS
[0013] Unless otherwise indicated, the term “about” means ± 10%of the indicated range.
[0014] When used herein, the term “alkenyl” is accorded its conventional meaning. Examples of alkenyl moieties include straight-chain and branched C2-20, C2-12 and C2-6 alkenyl such as vinyl, allyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2, 3-dimethyl-2-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 2-decenyl and 3-decenyl.
[0015] The term “alkyl” is accorded its conventional meaning. Examples of alkyl moieties include straight-chain and branched C1-20 alkyl, C1-12 alkyl, C1-6 alkyl, C1-4 alkyl, and C1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4, 4-dimethylpentyl, octyl, 2, 2, 4-trimethylpentyl, nonyl, decyl, undecyl, and dodecyl.
[0016] The term “alkynyl” is accorded its conventional meaning. Examples of alkynyl moieties include straight-chain and branched C2-20, C2-12 and C2-6 alkynyl, such as ethynyl and 2-propynyl (propargyl) .
[0017] The term “aryl” refers to a single all-carbon-backbone aromatic ring or a multiple condensed all-carbon-backbone ring system wherein at least one of the rings is aromatic. Examples include C6-20, C6-14, C6-12, and C2-10 rings and multiple condensed carbon ring systems (e.g., ring systems comprising 2, 3 or 4 rings) having 9 to 20 carbon atoms in which at least one ring is aromatic and wherein the other rings may be aromatic or not aromatic. The rings of multiple condensed ring systems may be connected to each other via fused, spiro, or bridged bonds when valency allows. Examples of aryl moieties include anthracenyl, azulenyl, fluorenyl, indanyl, indenyl, naphthyl, phenyl, phenanthrenyl, and 1, 2, 3, 4-tetrahydronaphthyl.
[0018] The term “cycloalkyl” refers to a saturated or partially unsaturated all carbon-backbone ring having 3 to 20 carbon atoms (e.g., C3-20, C3-15, C3-7, C4-6 and C6 cycloalkyl) . Examples include multicyclic carbocyles such as bicyclo [3.1.0] hexane and bicyclo [2.1.1] hexane, and polycyclic carbocycles, such as tricyclic and tetracyclic carbocycles. The rings of multiple condensed ring systems may be connected to each other via fused, spiro, and bridged bonds when valency allows. For example, multicyclic carbocycles may be connected to each other via a single carbon atom to form a spiro connection (e.g., spiropentane, spiro [4, 5] decane) , via two adjacent carbon atoms to form a fused connection (e.g., decahydronaphthalene, norsabinane, norcarane) , or via two non-adjacent carbon atoms to form a bridged connection (e.g., norbornane, bicyclo [2.2.2] octane) . Examples of cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [2.2.1] heptane, pinane, adamantane.
[0019] The term “cycloheteroalkyl” refers to a cyclic heteroalkyl moiety, defined below.
[0020] The term “halo” encompass fluoro, chloro, bromo, and iodo.
[0021] The term “heteroalkyl” refers to a saturated or partially unsaturated moiety having 3-to 20-atom backbone of carbon and at least one heteroatom (e.g., O, N, S) . Examples of heteroalkyl moieties include 2-8-membered, 2-6-membered, and 2-4-membered heteroalkyl moieties. Particular examples include alkoxyl, acyl (e.g., formyl, acetyl, benzoyl) , alkylamino (e.g., di- (C1-3-alkyl) amino) , arylamino, aryloxime, carbamates, carbamides, alkylcarbonyl, arylcarbonyl, aminocarbonyl, alkylaminocarbonyl, alkylsulfanyl, arylsulfanyl, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, alkylsulfonylamino, and arylsulfonylamino.
[0022] The term “heteroaryl” encompasses a single aromatic ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur (e.g., single aromatic rings of from 1 to 6 carbon atoms and 1-4 heteroatoms) . The term also encompasses multiple condensed ring systems that have at least one such aromatic ring. Examles include acridinyl, benzimidazolyl, benzofuranyl, benzoisothiazolyl, benzoisoxazolyl, benzoquinazolinyl, benzothiazolyl, benzoxazolyl, furyl, imidazolyl, indazolyl, indolyl, isoquinolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, phthalazinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrimidyl, pyrrolyl, quinolyl, quinoxalyl, quinazolinyl, quinolinyl, thienyl, tetrazolyl, thiadiazolyl, thiazolyl, triazinyl, and triazolyl.
[0023] The term “heterocycle” refers to a cyclic (monocyclic or polycyclic) heterocarbyl moiety which may be aromatic, partially aromatic, or non-aromatic. Heterocycles include heteroaryls. Examples include 4-10-membered, 4-7-membered, 6-membered, and 5-membered heterocycles such as aziridinyl, azetidinyl, benzo [1, 3] dioxolyl, benzoxazinyl, 1, 3-benzodioxolyl, 1, 4-benzodioxanyl, cinnolinyl, chromanyl, 2, 3-dihydro-benzo [1, 4] dioxinyl, dihydrooxazolyl, 1, 2-dihydropyridinyl, 2, 3-dihydrobenzofuranyl, 1, 4-dioxane, dioxolane, butyrolactam, furanyl, homopiperidinyl, hydantoinyl, isoindolinyl-1-one, 2-oxa-6-azaspiro [3.3] heptanyl, hydantoin, imidazolidin-2-one, imidazolidine, imidazolidinone, morpholinyl, oxetanyl, oxiranyl, phthalimidyl, piperazinyl, piperidinyl, pyrrolidinonyl, piperidinyl, pyrrolidinyl, pyrazolidine, spiro [cyclopropane-1, 1'-isoindolinyl] -3'-one, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, 1, 2, 3, 4-tetrahydroquinolyl, tetrahydrothiopyranyl, thiomorpholinyl, and valerolactamyl.
[0024] The term “heterocycloalkyl” refers to a cyclic (monocyclic or polycyclic) heteroalkyl.
[0025] The term “include” has the same meaning as “include, but are not limited to, ” and the term “includes” has the same meaning as “includes, but is not limited to. ” Similarly, the term “such as” has the same meaning as the term “such as, but not limited to. ”
[0026] The term “lower alkyl” refers to alkyl having from 1 to 6 carbon atoms, e.g., C1-4 alkyl. Examples include methyl, ethyl, propyl, isopropyl, and cyclobutyl.
[0027] The terms “manage, ” “managing” and “management” mean preventing the recurrence of the specified disease or disorder in a patient who has already suffered from the disease or disorder, and / or lengthening the time that a patient who has suffered from the disease or disorder remains in remission. The terms encompass modulating the threshold, development and / or duration of the disease or disorder or changing the way that a patient responds to the disease or disorder.
[0028] The term “pharmaceutically acceptable salt” refers to a salt that is generally recognized as safe to administer to a subject. Examples of pharmaceutically acceptable salts include acetate, chloride, diphosphate, hydrochloride, maleate, phosphate, potassium, sodium, and sulfate.
[0029] The terms “prevent, ” “preventing” and “prevention” contemplate an action that occurs before a patient begins to suffer from the specified disease or disorder, which inhibits or reduces the severity of the disease or disorder. The terms encompass prophylaxis.
[0030] A “prophylactically effective amount” of a compound is an amount sufficient to prevent a disease or condition, or one or more symptoms associated with the disease or condition, or prevent its recurrence. A “prophylactically effective amount” of a compound means an amount, alone or in combination with other agents, that provides a prophylactic benefit in the prevention of the disease. The term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
[0031] The terms “subject” and “patient” are used interchangeably. The terms “subject” and “subjects” refer to an animal, such as a non-primate mammal (e.g., cow, pig, horse, cat, dog, rat, and mouse) and a primate (e.g., monkey, a chimpanzee, human) . Preferred subjects are human (e.g., adult humans) .
[0032] A “therapeutically effective amount” of a compound is an amount sufficient to provide a therapeutic benefit in the treatment or management of a disease or condition, or to delay or minimize one or more symptoms associated with the disease or condition. A “therapeutically effective amount” of a compound means an amount, alone or in combination with other therapies, that provides a therapeutic benefit in the treatment or management of the disease or condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces, or avoids symptoms or causes of a disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.
[0033] The terms “treat, ” “treating” and “treatment” contemplate an action that occurs while a patient is suffering from a specified disease or disorder, which reduces the severity of the disease or disorder or retards or slows the progression of the disease or disorder.
[0034] Unless otherwise indicated, an adjective before a string of nouns should be construed to apply to each. For example, the phrase “optionally substituted pyridyl, pyrazyl, or furanyl” means the same as “optionally substituted pyridyl, optionally substituted pyrazyl, or optionally substituted furanyl” .
[0035] A dashed line “----” used to depict a bond in a chemical structure indicates that the bond may be delocalized (e.g., as in a tautomer) or may or may not exist (e.g., as in the case where a solid and a dashed line are used together to depict a bond that may exist as a single bond or a double bond) .
[0036] A wavy line that intersects a bond in a chemical structure indicates the point of attachment of the bond that the wavy bond intersects in the chemical structure to the remainder of a molecule.
[0037] Compounds disclosed herein may exist as tautomeric isomers. Although only one delocalized resonance structure may be depicted, all such forms are contemplated within the scope of the invention.
[0038] Compounds disclosed herein may exist as zwitterions (e.g., at pharmacological pH) . Unless otherwise indicated, it should be understood that a chemical drawing depicting the structure of such a compound encompasses all of its zwitterionic forms.
[0039] Some compounds may exist as stereoisomers. When a stereoisomer of compound is defined by its name (e.g., with the use of R or S) or is depicted in a drawn structure (e.g., using a bold, bold-wedge, dashed, or dashed-wedge to depict the relevant chemical bond) , the enantiomeric excess (ee) of that compound, unless otherwise indicated, is to be understood to be at least 60, 70, 80, 90, 95, or 99%. A compound or composition enriched with one stereoisomer of the compound has that one stereoisomer in an amount measurably greater than the compound’s other stereoisomer (s) . For example, a compound enriched with an R enantiomer will have an enantiomeric excess of that enantiomer versus the S enantiomer.
[0040] Unless explicitly noted, chemical structures named or shown herein encompass derivatives wherein one or more of their constituent atoms is / are replaced or enriched (i.e., present in a quantity measurably greater than its natural abundance) with an isotope thereof. Thus, unless noted otherwise, a chemical structure that contains hydrogen atoms encompasses deuterated forms of the represented molecule or moiety.
[0041] With regard to the claims, if a first claim recites a compound, which compound is defined as having a structure (or name) and salts (e.g., a pharmaceutically acceptable salts) thereof, a dependent claim that recites a compound of the first claim should, unless otherwise indicated, be construed as encompassing both the compound and its salts.
[0042] 3.2. COMPOUNDS OF THE INVENTION
[0043] This invention is directed, in part, to compounds of formula I
[0044] and pharmaceutically acceptable salt thereof, wherein: X1 is N, NRX1, S, or O; X2 is N, NRX2, S, or O; Z1 is N or CH; Z2 is N or CH; Z3 is N or C if at least one of Z1 and Z2 is CH; or Z3 is C if both Z1 and Z2 are N; L is a bond or -NH-; RX1 is H or C1-3 alkyl; RX2 is H or C1-3 alkyl; A1 is 4-9 membered heterocycloalkyl; A2 is aryl or 5-6 membered heteroaryl; R1 is H or optionally substituted C2-4 alkenyl or C2-4 alkynyl, which optional substitution is with at least one (e.g., one, two, or three) R1A; each R1A is independently cyano, halo, hydroxy, C1-6 alkyl, C1-6 alkoxy, -CH2- (4- (oxetan-3-yl) piperazin) , -CHCH3- (4- (oxetan-3-yl) piperazin) , or -C (CH3) 2- (4- (oxetan-3-yl) piperazin) ; each R2 is independently cyano, halo, NR2AR2B, or optionally substituted C2-4 alkynyl, C2-4 alkenyl, C1-6 alkyl, C3-6 cycloalkyl, C3-6 heterocycloalkyl, or C1-6 alkoxy, which optional substitution is with at least one (e.g., one, two, or three) of halo or C1-3 alkyl; R2A is H, C1-3 alkyl, or oxetan; R2B is H or C1-3 alkyl; each R3 is independently halo; each R4 is independently halo, cyano, or optionally substituted C1-3 alkyl or C3-6 cycloalkyl, which optional substitution is with at least one (e.g., one, two, or three) halo; n is 0-3; m is 0-2; and p is 0-2.
[0045] In some chemical formulae, an asterisk (*) is used to aid in specifying the stereochemistry at the atom in A1 to which Z2 is bound: it has no chemical meaning. In particular compounds of the invention, the stereochemistry at that position is (R) .
[0046] Some compounds of the invention are of formula II
[0047] wherein Y is CH2 or O. Some compounds of the invention are of formula III
[0048] wherein Z4 is N or CH.
[0049] In some compounds, A1 is pyrrolidine or piperidine. In some compounds, A2 is imidazolyl, isoxazolyl, oxazolyl, phenyl, pyrazolyl, pyridyl, or thiazolyl.
[0050] Some compounds of the invention are of formula IV
[0051] wherein Y is CH2 or O.
[0052] Some compounds are of formula V
[0053] wherein Y is CH2 or O.
[0054] In some compounds, Y is CH2.
[0055] In some compounds, Z4 is N.
[0056] In some compounds, X1 is N. In some compounds, X2 is O or S. In some compounds, X1 is N and X2 is O.
[0057] In some compounds, m is 0.
[0058] In some compounds, n is 1. In some compounds, n is 2.
[0059] In some compounds, R2 is independently halo or optionally substituted C1-6 alkyl (e.g., methyl, C1-6 alkyl substituted with one or more halo) .
[0060] In some compounds, p is 0. In some compounds, p is 1.
[0061] In some compounds, R4 is optionally substituted C1-3 alkyl (e.g., methyl) .
[0062] In some compounds, L is a bond.
[0063] In some compounds, R1 is optionally substituted C2-4 alkenyl. In some compounds, R1 is -CH=CH2. In some, R1 is -CH=CH2 substituted with halo. In some, R1 is -CH=CH2 substituted with cyano.
[0064] Specific compounds of the invention include those shown below in Table 1 and pharmaceutically acceptable salts thereof.
[0065] Table 1
[0066] Preferred compounds of the invention inhibit the phosphorylation activity of active ITK, of active BTK, or both. Inhibitory activity can be measured using methods and assays well known in the art, including the biochemical assays and cell-based assays described herein. Preferred compounds inhibit ITK’s phosphorylation of labeled Peptide 27 in vitro with an IC50 of less than 500, 250, 100, 50, 25, 10, or 5 nM. Preferred compounds inhibit IL-2 production in Jurkat cells with an IC50 of less than 1000, 750, 500, 300, 250, 100, or 50 nM. Preferred compounds inhibit BTK’s phosphorylation of labeled Peptide 2 in vitro with an IC50 of less than 500, 250, 100, 50, 25, 10, or 5 nM. Preferred compounds inhibit CD69 expression in human peripheral blood mononuclear cells with an IC50 of less than 250, 200, 150, 100, 50, 25, or 10 nM. Particular compounds ( “dual inhibitors” ) inhibit both ITK and BTK with an in vitro biochemical assay IC50 of less than about 25, 10, or 5 nM. Particular compounds inhibit both IL-2 production in Jurkat cells and CD69 expression in human peripheral blood mononuclear cells.
[0067] 3.2.1. Methods of Synthesis
[0068] Compounds of the invention can be prepared using methods known in the art, methods described in the general reaction schemes below, and methods described in the detailed examples provided herein. One general synthetic approach is shown below in Scheme 1, wherein ring A1 may be substituted with one or more R4 as defined elsewhere herein.
[0069] Scheme 1
[0070] In this approach, a benzo [d] oxazole-based compound of Formula A is prepared by coupling optionally substituted aryl or heterocycle 1a with aryl amine 1b under suitable reaction conditions (e.g., hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU) , triethylamine (TEA) , dimethylformamide (DMF) , at room temperature) to provide intermediate 1c, which is cyclized (e.g., using phosphoric acid (PPA) at 150℃) to provide compound 1d. Compound 1d is converted to a corresponding boronic ester 1e (e.g., using Pd (dppf) Cl2, potassium acetate (AcOK) , dioxane, 100 ℃) , which then undergoes Suzuki coupling with protected compound 1f (e.g., using Pd (dppf) Cl2, K2CO3, dioxane / H2O, 100℃) to afford intermediate 1g. The protective group is then replaced under suitable conditions (e.g., trifluoroacetic acid (TFA) and dichloromethane (DCM) at room temperature followed by NaHCO3 and THF / H2O at room temperature) to afford compound A.
[0071] Another general synthetic method useful in preparing compounds of the invention is shown below in Scheme 2, wherein ring A1 may be substituted with one or more R4 as defined elsewhere herein.
[0072] Scheme 2
[0073] In this approach, a benzo [d] thiazole-based compound of formula B is prepared by contacting optionally substituted aryl or heterocycle 2a with optionally substituted 2-amino-5-bromobenzenethiol 2b under conditions sufficient (e.g., triphenylphosphine (TPP) , tetrabutylammonium bromide (TBAB) , 120℃) to form intermediate 2c. Compound 2c is converted to a corresponding boronic ester 2d (e.g., using Pd (dppf) Cl2, AcOK, dioxane, 100 ℃) , which then undergoes Suzuki coupling with protected compound 2e (e.g., using Pd (dppf) Cl2, K2CO3, dioxane / H2O, 100℃) to afford intermediate 2f. The protective group is then replaced under suitable conditions (e.g., trifluoroacetic acid (TFA) and dichloromethane (DCM) at room temperature followed by NaHCO3 and THF / H2O at room temperature) to afford compound B.
[0074] Another general synthetic method useful in preparing compounds of the invention is shown below in Scheme 3, wherein ring A1 may be substituted with one or more R4 as defined elsewhere herein.
[0075] Scheme 3
[0076] In this approach, a benzo [d] thiazole-based compound of formula C is prepared by contacting optionally substituted benzo [d] thiazole 3a with optionally substituted aniline or heterocycle-amine 3b under conditions sufficient (e.g., NaH, THF, room temperature) to form intermediate 3c. Compound 3c is converted to a corresponding boronic ester 3d (e.g., using Pd(dppf) Cl2, AcOK, dioxane, 100 ℃) , which then undergoes Suzuki coupling with protected compound 3e (e.g., using Pd (dppf) Cl2, K2CO3, dioxane / H2O, 100℃) to afford intermediate 3f. The protective group is then replaced under suitable conditions (e.g., trifluoroacetic acid (TFA) and dichloromethane (DCM) at room temperature followed by NaHCO3 and THF / H2O at room temperature) to afford compound C.
[0077] Another general synthetic method useful in preparing compounds of the invention is shown below in Scheme 4, wherein ring A1 may be substituted with one or more R4 as defined elsewhere herein.
[0078] Scheme 4
[0079] In this approach, an imidazo [1, 5-a] pyrazine-based compound of formula D is prepared from 4a, which is brominated by NBS to afford 4b, which is reacted with ammonia form intermediate 4c. Compound 4c undergoes Suzuki coupling to afford intermediate 4d. The protective group is then replaced under suitable conditions (e.g., trifluoroacetic acid (TFA) and trifluoromethanesulfonic acid (CF3SO3H) ) , followed by NaHCO3 and THF / H2O at room temperature to afford compound D.
[0080] 3.3. METHODS OF USE
[0081] This invention encompasses methods of inhibiting ITK and / or BTK, which comprise contacting (in vitro or in vivo) ITK or BTK with a compound of the invention. It also encompasses methods of treating, managing, and preventing diseases associated with ITK or BTK activity, overexpression, or mutation, which methods comprise administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound of the invention.
[0082] This invention further encompasses a method of increasing T-cell activation, which comprises administering to a patient in need thereof an effective amount of a compound of the invention.
[0083] This invention also encompasses methods of treating diseases and conditions, methods of managing diseases or conditions, and methods of preventing diseases or conditions. For example, this invention encompasses methods of treating, managing, or preventing an autoimmune or inflammatory disease or condition, which comprise administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound of the invention. Examples of autoimmune and inflammatory diseases or conditions include acne vulgaris, Addition’s disease, alopecia areata, ankylosing spondylitis, asthma, atherosclerosis, atopic dermatitis, autoimmune hemolytic anemia, Behcet’s disease, celiac disease, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, Crohn’s disease, diabetes mellitus type I, eosinophilic esophagitis, erythematosus, Goodpasture syndrome, graft-versus-host disease, Graves’ disease, Hashimoto’s encephalopathy, Hashimoto's thyroiditis, idiopathic thrombocytopenic purpura, IgA nephropathy, ischemia reperfusion injury, juvenile onset diabetes, lupus nephritis, multiple sclerosis, neuromyelitis optica spectrum disease (NMOSD) , oligodendrocyte glycoprotein (MOG) immunoglobulin G-associated disease (MOGAD) , pemphigus primary membranous nephropathy, prurigo nodularis, psoriasis, psoriatic arthritis, reperfusion injury, rheumatoid arthritis, scleroderma, syndrome, stroke, systemic lupus, ulcerative colitis, vasculitis, and vitiligo.
[0084] Another embodiment of the invention encompasses methods of treating, managing, or preventing cancer, which comprise administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound of the invention. Examples of cancers include bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck squamous cell carcinoma, hematologic cancer, lung cancer, Merkel-cell carcinoma, melanoma, mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small cell lung cancer, transitional cell carcinoma, and urothelial cancer.
[0085] Examples of hematological cancers include B-cell malignancies such as Non-lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, and macroglobulinemia; T-cell malignancies such as Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS) , Nodal T-follicular helper (TFH) lymphoma, angioimmunoblastic type (AITL) , Extra-nodal NK-T cell lymphoma (ENKTL) , Enteropathy associated T-cell lymphoma (EATL) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) , Hepatosplenic T-cell lymphoma (HSTCL) , Adult T-cell leukemia / lymphoma (ATLL) , Mycosis fungoides (MF) , Sezary syndrome (SS) ; and leukemia.
[0086] In preferred methods of the invention, the ITK or BTK inhibitor is administered to a patient orally. In others, it is administered by another therapeutically or prophylactically effective route (e.g., intravenously) . The amount of an inhibitor and the frequency of its dosing can be determined by a physician (e.g., oncologist) using methods well-known in the art.
[0087] 3.4. PHARMACEUTICAL FORMULATIONS
[0088] Compounds disclosed herein may be systemically administered in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable, edible carrier. They may be in the form of single unit dosage forms (e.g., enclosed in hard or soft shell gelatin capsules or compressed into tablets) . For oral therapeutic administration, an active compound may be combined with one or more excipients in the form of ingestible tablets, buccal tablets, capsules, caplets, troches, elixirs, suspensions, syrups, and wafers.
[0089] Compounds may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of an active compound or its salts may be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
[0090] Pharmaceutical dosage forms suitable for injection or infusion may include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like) , vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0091] Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
[0092] 3.5. EXAMPLES
[0093] The following examples include descriptions of the synthesis and characterization of specific compounds of the invention, methods used to measure their ability to inhibit kinases, and results obtained using those methods.
[0094] 3.5.1. Synthesis of tert-butyl (R) -3- (3-bromo-4- ( (2, 4-dimethoxybenzyl) amino) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (Intermediate A)
[0095] Step A: 3-bromo-4-chloro-1H-pyrazolo [4, 3-c] pyridine
[0096] To a solution of 4-chloro-1H-pyrazolo [4, 3-c] pyridine (8 g, 52.09 mmol) in MeCN (60 mL) was added NBS (9.27 g, 52.09 mmol) at room temperature. The reaction mixture was stirred at 80℃ for 3h. The reaction mixture was quenched by aqueous (aq) NaHCO3 (30 mL) and extracted with EA (3 x 30 mL) . The combined organic phase was washed with brine (30 mL) , dried over anhydrous Na2SO4, filtered and concentrated to give 3-bromo-4-chloro-1H-pyrazolo [4, 3-c] pyridine (12 g, 51.62 mmol, 99.09%) as a yellow solid. ESI-MS m / z: 231.9 [M+H] +.
[0097] Step B: (R) -tert-butyl 3- (3-bromo-4-chloro-1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate
[0098] To a mixture of (S) -tert-butyl 3-hydroxypiperidine-1-carboxylate (24.24 g, 120.45 mmol) in THF (150 mL) were added PPh3 (31.59 g, 120.45 mmol) and DIAD (24.36 g, 120.45 mmol) at 0℃. The reaction mixture was degassed with N2 and stirred at room temperature for 15 minutes (min) , then the mixture was added 3-bromo-4-chloro-1H-pyrazolo [4, 3-c] pyridine (14 g, 60.22 mmol) . The reaction mixture was stirred at 50℃ overnight. The mixture was quenched with H2O (100 mL) and extracted with EA (2 x 150 mL) . The combined organic phase was washed with brine (30 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography (PE / EA = 3 / 1) to give (R) -tert-butyl 3- (3-bromo-4-chloro-1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (13.5 g, 32.47 mmol, 53.92%) as a colorless oil. ESI-MS m / z: 414.9 [M+H] +.
[0099] Step C: (R) -tert-butyl 3- (3-bromo-4- (2, 4-dimethoxybenzylamino) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate
[0100] To a solution of (R) -tert-butyl 3- (3-bromo-4-chloro-1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (8.5 g, 20.45 mmol) in MeCN (120 mL) were added (2, 4-dimethoxyphenyl) methanamine (17.09 g, 102.23 mmol) and DIEA (13.21 g, 102.23 mmol) . The reaction mixture was stirred at 100℃ overnight in a sealed tube. The reaction mixture was filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE / EA = 1 / 1) to give (R) -tert-butyl 3- (3-bromo-4- (2, 4-dimethoxybenzylamino) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (6.3 g, 11.53 mmol, 56.38%) as a yellow oil. ESI-MS m / z: 546.1 / 548.4 [M+H] +.
[0101] 3.5.2. Synthesis of tert-butyl (R) -3- (4-amino-3-bromo-1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidine-1-carboxylate (Intermediate B)
[0102] Step A: (R) -tert-butyl 3- (4-amino-3-bromo-1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidine-1-carboxylate
[0103] To a mixture of 3-bromo-1H-pyrazolo [3, 4-d] pyrimidin-4-amine (8 g, 37.38 mmol) in THF (150 mL) were added PPh3 (11.77 g, 44.86 mmol) and DIAD (9.07 g, 44.86 mmol) at 0℃. The reaction mixture was degassed with N2 and stirred at room temperature for 15 min, then the mixture was added (S) -tert-butyl 3-hydroxypiperidine-1-carboxylate (12.79 g, 63.54 mmol) . The reaction mixture was stirred at 25℃ overnight. The mixture was quenched with H2O (100 mL) and extracted with EA (150 mL × 2) and the organic layer was dried over Na2SO4, filtered and concentrated under reduce pressure. The crude residue was purified by column chromatography (PE / EA = 1 / 1) to give (R) -tert-butyl 3- (4-amino-3-bromo-1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidine-1-carboxylate (12 g, 30.21 mmol, 80.81%) as a white solid. ESI-MS m / z: 397.1 / 399.1 [M+H] +.
[0104] 3.5.3. Synthesis of (R) -1- (3- (4-amino-3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one (Compound 1)
[0105] Step A: N- (4-bromo-2-hydroxyphenyl) -6-chloro-5-methylpicolinamide
[0106] To a solution of 6-chloro-5-methylpyridine-2-carboxylic acid (1000 mg, 5.83 mmol) and HATU (2437.72 mg, 6.41 mmol) and TEA (1.37 mL, 9.91 mmol) in DMF (30 mL) was added 2-amino-5-bromophenol (1095.82 mg, 5.83 mmol) . The reaction mixture was degassed with N2 and stirred at room temperature for 16h. The reaction mixture was diluted with water (3 x 50 mL) and extracted with EA (50 mL) . The combined organic phase was washed with brine (30 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE / EA = 1 / 2) to give N- (4-bromo-2-hydroxyphenyl) -6-chloro-5-methylpicolinamide (1.4 g, 4.10 mmol, 70.32%) as a yellow solid. ESI-MS m / z: 341.0 [M+H] +.
[0107] Step B: 6-bromo-2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazole
[0108] A mixture of N- (4-bromo-2-hydroxyphenyl) -6-chloro-5-methylpicolinamide (500 mg, 1.46 mmol) in PPA (10 mL) was stirred at 150℃ for 3 hours (h) . The reaction mixture was diluted with water (50 mL) and the solids was collected by filtration. The filter cake was washed with NaHCO3 solution (3 x 30 mL) and dried to give 6-bromo-2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazole (400 mg, 1.24 mmol, 84.46%) as a brown solid. ESI-MS m / z: 323.0 [M+H] +.
[0109] Step C: 2- (6-chloro-5-methylpyridin-2-yl) -6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzo [d] oxazole
[0110] A mixture of 6-bromo-2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazole (400 mg, 1.24 mmol) , 4, 4, 5, 5-tetramethyl-2- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 3, 2-dioxaborolane (376.71 mg, 1.48 mmol) , Pd (dppf) Cl2 (90.37 mg, 0.12 mmol) and AcOK (363.45 mg, 3.71 mmol) in dioxane (15 mL) was stirred at 100℃ for 16h. The reaction mixture was diluted with water (30 mL) and extracted with EA (3 x 30 mL) . The combined organic phase was washed with brine (30 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE / EA = 1 / 5) to give 2- (6-chloro-5-methylpyridin-2-yl) -6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzo [d] oxazole (120 mg, 0.32 mmol, 26.19%) as a pink solid. ESI-MS m / z: 371.1 [M+H] +.
[0111] Step D: (R) -tert-butyl 3- (3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -4- (2, 4-dimethoxybenzylamino) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate
[0112] A mixture of (R) -tert-butyl 3- (3-bromo-4- (2, 4-dimethoxybenzylamino) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (130 mg, 0.24 mmol) , 2- (6-chloro-5-methylpyridin-2-yl) -6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzo [d] oxazole (96.99 mg, 0.26 mmol) , Pd (dppf) Cl2 (17.39 mg, 0.02 mmol) and potassium carbonate (98.63 mg, 0.71 mmol) in dioxane (5 mL) / water (1 mL) was stirred at 100℃ for 16h. The reaction mixture was diluted with water (30 mL) and extracted with EA (3 x 30 mL) . The combined organic phase was washed with brine (30 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE / EA = 1 / 1) to give (R) -tert-butyl 3- (3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -4- (2, 4-dimethoxybenzylamino) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (110 mg, 0.15 mmol, 65.10%) as a yellow solid. ESI-MS m / z: 709.7 [M+H] +.
[0113] Step E: (R) -3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1- (piperidin-3-yl) -1H-pyrazolo [4, 3-c] pyridin-4-amine
[0114] To a solution of (R) -tert-butyl 3- (3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -4- (2, 4-dimethoxybenzylamino) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (110 mg, 0.15 mmol) in TFA (2 mL) was added Et3SiH (17.97 mg, 0.15 mmol) at room temperature and the reaction mixture was stirred at 80℃ for 2h. The reaction mixture was diluted with NaHCO3 solution (50 mL) and extracted with EA (3 x 30 mL) . The combined organic phase was washed with brine (30 mL) , dried over anhydrous Na2SO4, filtered and concentrated to give (R) -3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1- (piperidin-3-yl) -1H-pyrazolo [4, 3-c] pyridin-4-amine (71 mg, 0.15 mmol, 99.67%) as a yellow oil, which was used directly in next step without further purification. ESI-MS m / z: 460.2 [M+H] +.
[0115] Step F: (R) -1- (3- (4-amino-3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one
[0116] To a mixture of (R) -3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1- (piperidin-3-yl) -1H-pyrazolo [4, 3-c] pyridin-4-amine (71 mg, 0.15 mmol) in THF (5 mL) and NaHCO3 (5 mL) was added acryloyl chloride (13.97 mg, 0.15 mmol) . The reaction mixture was stirred at room temperature for 10 min. The reaction mixture was diluted with water (30 mL) and extracted with EA (3 x 30 mL) . The combined organic phase was washed with brine (30 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The crude residue was purified by prep-HPLC to give (R) -1- (3- (4-amino-3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one (13.86 mg, 0.03 mmol, 17.47%) as a white solid. ESI-MS m / z: 513.7 [M+H] +. 1H NMR (400 MHz, DMSO-d6) δ 8.36 (d, J = 7.7 Hz, 1H) , 8.15 (d, J = 7.7 Hz, 2H) , 8.06 (d, J = 8.2 Hz, 1H) , 7.84 (dd, J = 27.7, 7.0 Hz, 2H) , 7.13 –6.72 (m, 2H) , 6.17 (dd, J = 37.5, 16.9 Hz, 1H) , 5.95 (s, 2H) , 5.72 (dd, J = 53.6, 10.2 Hz, 1H) , 4.85 –4.57 (m, 1.5H) , 4.40 –4.11 (m, 1.5H) , 3.78 –3.69 (m, 0.5H) , 3.27 (t, J = 11.8 Hz, 1H) , 3.08 –3.00 (m, 0.5H) , 2.53 (s, 3H) , 2.28 –2.25 (m, 2H) , 2.05 –1.97 (m, 1H) , 1.71 –1.68 (m, 1H) .
[0117] 3.5.4. Synthesis and Characterization of Compounds 2-23 and 70-74
[0118] The following compounds (compounds 2-23 and 70-74) were prepared by the method described above in Example 3.5.3.
[0119] Table 2
[0120] 3.5.5. Synthesis of (R) -1- (3- (4-amino-3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one (Compound 24)
[0121] Step A: (R) -tert-butyl 3- (4-amino-3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidine-1-carboxylate
[0122] To a solution of (R) -tert-butyl 3- (4-amino-3-bromo-1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidine-1-carboxylate (280 mg, 0.70 mmol) in dioxane (20 mL) and H2O (4 mL) was added 2- (6-chloro-5-methylpyridin-2-yl) -5- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzo [d] oxazole (261.22 mg, 0.70 mmol) , Pd (dppf) Cl2 (51.22 mg, 0.07 mmol) and K2CO3 (193.48 mg, 1.40 mmol) . The reaction mixture was degassed with N2 and stirred at 120℃ overnight in a sealed tube. The reaction mixture was diluted with H2O (15 mL) and extracted with EA (3 x 50 mL) . The combined organic phase was washed with brine (30 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE / EA = 1 / 10) to give (R) -tert-butyl 3- (4-amino-3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidine-1-carboxylate (210 mg, 0.37 mmol, 53.11%) as a yellow oil. ESI-MS m / z: 561.2 [M+H] +.
[0123] Step B: (R) -3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1- (piperidin-3-yl) -1H-pyrazolo [3, 4-d] pyrimidin-4-amine
[0124] To a solution of (R) -tert-butyl 3- (4-amino-3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidine-1-carboxylate (210 mg, 0.37 mmol) in DCM (10 mL) was added TFA (2 mL, 26.14 mmol) and the reaction mixture was stirred at room temperature for 2h. The reaction mixture was quenched with NaHCO3 (15 mL) and extracted with EA (3 x 50 mL) . The combined extracts were dried over anhydrous Na2SO4, filtered and concentrated to give (R) -3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1- (piperidin-3-yl) -1H-pyrazolo [3, 4-d] pyrimidin-4-amine (150 mg, 0.33 mmol, 86.94%) as a yellow oil, which was used directly in next step without further purification. ESI-MS m / z: 461.2 [M+H] +.
[0125] Step C: (R) -1- (3- (4-amino-3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one
[0126] To a mixture of (R) -3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1- (piperidin-3-yl) -1H-pyrazolo [3, 4-d] pyrimidin-4-amine (150 mg, 0.33 mmol) and NaHCO3 solution (3 mL) in THF (3 mL) was added acryloyl chloride (29.45 mg, 0.33 mmol) dropwise at room temperature. The reaction mixture was stirred at room temperature for 10 min. The reaction mixture was extracted with EA (3 x 10 mL) . The combined organic phase was washed with brine (10 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC to give (R) -1- (3- (4-amino-3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one (44.04 mg, 0.09 mmol, 26.28%) as a white solid. ESI-MS m / z: 515.2 [M+H] +. 1H NMR (400 MHz, DMSO-d6) δ 8.26 (d, J = 8.1 Hz, 2H) , 8.05 (d, J = 8.1 Hz, 2H) , 7.96 (d, J = 8.2 Hz, 1H) , 7.72 (d, J = 8.1 Hz, 1H) , 7.64 –6.60 (m, 3H) , 6.18-6.03 (m, 1H) , 5.74-5.56 (m, 1H) , 4.85 –4.01 (m, 3H) , 3.82 –3.69 (m, 0.5H) , 3.30 –3.16 (m, 1H) , 3.06 (s, 0.5H) , 2.44 (s, 3H) , 2.35-2.23 (m, 1H) , 2.18 –2.14 (m, 1H) , 1.96 –1.93 (m, 1H) , 1.62 –1.58 (m, 1H) .
[0127] 3.5.6. Synthesis and Characterization of Compounds 25-47 and 64-69
[0128] Compounds 25-47 and 64-69 were prepared by the method described in above in Example 3.5.5. Characterization data for the compounds is provided in Table 3.
[0129] Table 3
[0130] 3.5.7. Synthesis of (R) -1- (3- (4-amino-3- (5-chloro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one (Compound 48)
[0131] Step A: 2-amino-5-bromo-4-chlorophenol
[0132] To a solution of 4-bromo-5-chloro-2-methoxyaniline (4.9 g, 20.72 mmol) in DCM (20 mL) was added 1N BBr3 (41.44 mL) in DCM at 0℃ under N2 and stirred at RT for 3h. Then the reaction mixture was quenched with aq. NaHCO3 and concentrated, the residue was extracted with EA and washed with brine. The combined organic layer was dried over Na2SO4, filtered and concentrated to afford 2-amino-5-bromo-4-chlorophenol (2.6 g, 11.69 mmol, 56.41%) as black solid. ESI-MS m / z: 221.9 / 223.9 [M+H] +.
[0133] Step B: N- (4-bromo-5-chloro-2-hydroxyphenyl) -5-methylpicolinamide
[0134] To a solution of 2-amino-5-bromo-4-chlorophenol (500 mg, 2.25 mmol) in DMF (10 mL) was added 5-methylpyridine-2-carboxylic acid (308.22 mg, 2.25 mmol) , HATU (1025.50 mg, 2.70 mmol) and DIEA (1.24 mL, 6.74 mmol) at RT and the reaction mixture was stirred at room temperature (RT) for 2h. The mixture was filtered, the filter cake was dried to afford N- (4-bromo-5-chloro-2-hydroxyphenyl) -5-methylpicolinamide (350 mg, 1.02 mmol, 45.59%) as a yellow solid. ESI-MS m / z: 340.9 / 342.9 [M+H] +.
[0135] Step C: 6-bromo-5-chloro-2- (5-methylpyridin-2-yl) benzo [d] [1, 3] oxazole
[0136] To a solution of N- (4-bromo-5-chloro-2-hydroxyphenyl) -5-methylpicolinamide (350 mg, 1.02 mmol) in PPA (3 mL) was stirred at 150℃ for 1h. The reaction mixture was added H2O, yellow solid was precipitated, filtered to give 6-bromo-5-chloro-2- (5-methylpyridin-2-yl) benzo [d] [1, 3] oxazole (250 mg, 0.77 mmol, 75.41%) as a yellow solid. ESI-MS m / z: 322.9 / 324.9 [M+H] +.
[0137] Step D: (5-chloro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) boronic acid
[0138] To a solution of 6-bromo-5-chloro-2- (5-methylpyridin-2-yl) benzo [d] [1, 3] oxazole (95 mg, 0.29 mmol) in dioxane (5 mL) was added 4, 4, 5, 5-tetramethyl-2- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 3, 2-dioxaborolane (111.83 mg, 0.44 mmol) , Pd (dppf) Cl2 (21.48 mg, 0.03 mmol) and KOAc (86.44 mg, 0.88 mmol) , the reaction mixture was degassed with N2 and stirred at 100℃ for 4h. Then the reaction mixture was cooled to RT and used directly in next step without further purification. ESI-MS m / z: 288.9 / 290.9 [M+H] +.
[0139] Step E: tert-butyl (R) -3- (3- (5-chloro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -4- ( (2, 4-dimethoxybenzyl) amino) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate
[0140] To a solution of (5-chloro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) boronic acid (43 mg, 0.15 mmol) in dioxane (2 mL) and H2O (0.5 mL) was added tert-butyl (R) -3- (3-bromo-4- ( (2, 4-dimethoxybenzyl) amino) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (81.45 mg, 0.15 mmol) , Pd (dppf) Cl2 (10.91 mg, 0.01 mmol) and K2CO3 (61.80 mg, 0.45 mmol) , the reaction mixture was degassed with N2 and stirred at 100℃ for 2h. Then the reaction mixture was concentrated, the residue was purified by chromatography on silica gel (0-90%, EA in PE) to afford tert-butyl (R) -3- (3- (5-chloro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -4- ( (2, 4-dimethoxybenzyl) amino) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (75 mg, 0.11 mmol, 70.85%) as a yellow oil. ESI-MS m / z: 710.3 [M+H] +.
[0141] Step F: (R) -3- (5-chloro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1- (piperidin-3-yl) -1H-pyrazolo [4, 3-c] pyridin-4-amine
[0142] To a solution of tert-butyl (R) -3- (3- (5-chloro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -4- ( (2, 4-dimethoxybenzyl) amino) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (75 mg, 0.11 mmol) in TFA (2 mL) was added Et3SiH (24.56 mg, 0.21 mmol) at RT and the reaction mixture was stirred at 80℃ for 10 min. The reaction mixture was concentrated to give (R) -3- (5-chloro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1- (piperidin-3-yl) -1H-pyrazolo [4, 3-c] pyridin-4-amine (45 mg, 0.10 mmol, 92.65%) as a yellow oil, which was used directly in next step without further purification. ESI-MS m / z: 460.1 [M+H] +.
[0143] Step G: (R) -1- (3- (4-amino-3- (5-chloro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one
[0144] To a solution of (R) -3- (5-chloro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1- (piperidin-3-yl) -1H-pyrazolo [4, 3-c] pyridin-4-amine (45 mg, 0.10 mmol) in THF (3 mL) and H2O (0.5 mL) was added NaHCO3 (16.44 mg, 0.20 mmol) and prop-2-enoyl chloride (8.86 mg, 0.10 mmol) at 0℃ and the reaction mixture was stirred at 0℃ for 10 min. The reaction mixture was quenched with H2O, and concentrated. The residue was purified by Pre-HPLC (0-40%, MeCN in H2O, 0.05%TFA) to afford (R) -1- (3- (4-amino-3- (5-chloro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one (12.26 mg, 0.02 mmol, 23.89%) as a white solid. ESI-MS m / z: 514.1 [M+H] +. 1H NMR (400 MHz, DMSO-d6) δ 12.81 (s, 1H) , 8.69 (d, J = 2.0 Hz, 1H) , 8.31 (d, J = 8.0 Hz, 1H) , 8.22 (s, 1H) , 8.13 (s, 1H) , 7.96 –7.83 (m, 3H) , 7.48 (t, J = 6.5 Hz, 1H) , 6.90 (dd, J = 16.6, 10.6 Hz, 1H) , 6.13 (dd, J = 29.8, 16.3 Hz, 1H) , 5.69 (dd, J = 43.6, 10.5 Hz, 1H) , 4.91 (d, J = 40.3 Hz, 1H) , 4.60 –4.05 (m, 2H) , 3.32 –3.20 (m, 2H) , 2.45 (s, 4H) , 2.18 (s, 2H) , 1.93 (s, 1H) , 1.64 (s, 1H) .
[0145] 3.5.8. Synthesis and Characterization of (R) -1- (3- (4-amino-3- (5-chloro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one (Compound 50)
[0146] Compound 50 was prepared by the method described above in Example 3.5.7 and was characterized by electrospray ionization mass spectrometry (ESI-MS) : m / z: 515.1 [M+H] +.
[0147] 3.5.9. Synthesis of (R) -1- (3- (4-amino-3- (7-fluoro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one (Compound 51)
[0148] Step A: N- (5-bromo-3-fluoro-2-hydroxyphenyl) -5-methylpicolinamide
[0149] A mixture of 5-methylpicolinic acid (272.94 mg, 1.99 mmol) , 2-amino-4-bromo-6-fluorophenol (410 mg, 1.99 mmol) , DCC (821.27 mg, 3.98 mmol) and HOBt (537.87 mg, 3.98 mmol) in toluene (10 mL) was stirred at 30℃ for 1h. The reaction mixture was diluted with ice water (50 mL) and extracted with EA (3 x 50 mL) . The combined organic phase was washed with brine (50 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE / EA = 1 / 1) to give N- (5-bromo-3-fluoro-2-hydroxyphenyl) -5-methylpicolinamide (250 mg, 39%yield) as a yellow solid. ESI-MS m / z: 324.9, 326.9 [M+H] +.
[0150] Step B: 5-bromo-7-fluoro-2- (5-methylpyridin-2-yl) benzo [d] oxazole
[0151] A mixture of N- (5-bromo-3-fluoro-2-hydroxyphenyl) -5-methylpicolinamide (150 mg, 0.46 mmol) , DIAD (186.58 mg, 0.92 mmol) and PPh3 (242.01 mg, 0.92 mmol) in THF (3 mL) was stirred at 60℃ for 1h. The reaction mixture was concentrated. The residue was purified by flash chromatography on silica gel (PE / EA = 10 / 1) to give 5-bromo-7-fluoro-2- (5-methylpyridin-2-yl) benzo [d] oxazole (80 mg, 56%yield) as a yellow solid. ESI-MS m / z: 306.9, 308.9 [M+H] +.
[0152] Step C: tert-butyl (R) -3- (4- ( (2, 4-dimethoxybenzyl) amino) -3- (7-fluoro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate
[0153] A mixture of 5-bromo-7-fluoro-2- (5-methylpyridin-2-yl) benzo [d] oxazole (80 mg, 0.26 mmol) , B2Pin2 (132.29 mg, 0.52 mmol) , Pd (dppf) Cl2 (38.12 mg, 0.05 mmol) , KOAc (51.13 mg, 0.52 mmol) in dioxane (5 mL) was stirred at 110℃ for 1.5h under N2 atmosphere. Then tert-butyl (R) -3- (3-bromo-4- ( (2, 4-dimethoxybenzyl) amino) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (70 mg, 0.13 mmol) , K2CO3 (72.00 mg, 0.52 mmol) and H2O (1 mL) was added to mixture and the mixture was continue stirred at 110℃ for 2h under N2 atmosphere. The reaction mixture was diluted with ice water (20 mL) and extracted with EA (3 x 20 mL) . The combined organic phase was washed with brine (20 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE / EA = 1 / 1) to give tert-butyl (R) -3- (4- ( (2, 4-dimethoxybenzyl) amino) -3- (7-fluoro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (60 mg, 33%yield) as a yellow solid. ESI-MS m / z: 694.8 [M+H] +.
[0154] Step D: (R) -3- (7-fluoro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1- (piperidin-3-yl) -1H-pyrazolo [4, 3-c] pyridin-4-amine
[0155] A mixture of tert-butyl (R) -3- (4- ( (2, 4-dimethoxybenzyl) amino) -3- (7-fluoro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (60 mg, 0.09 mmol) , Et3SiH (20.11 mg, 0.17 mmol) in TFA (3 mL) was stirred at 80℃ for 0.5h. The reaction mixture was concentrated to give (R) -3- (7-fluoro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1- (piperidin-3-yl) -1H-pyrazolo [4, 3-c] pyridin-4-amine (39 mg, 98%yield) as a yellow oil. ESI-MS m / z: 444.2 [M+H] +.
[0156] Step E: (R) -1- (3- (4-amino-3- (7-fluoro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one
[0157] To a mixture of (R) -3- (7-fluoro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1-(piperidin-3-yl) -1H-pyrazolo [4, 3-c] pyridin-4-amine (39 mg, 0.09 mmol) and saturated NaHCO3 aq.(0.41 mL, 0.44 mmol) in THF (3 mL) was added dropwise prop-2-enoyl chloride (7.96 mg, 0.09 mmol) at ice bath and then the mixture was stirred at RT for 5min. The reaction mixture was filtered and the filtrate was purified by reverse phase chromatography eluted with CH3CN: H2O = 1: 10 ~ 10: 1 to give the title compound (R) -1- (3- (4-amino-3- (7-fluoro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one (10.5 mg, 24%yield) as a white solid. ESI-MS m / z: 498.1 [M+H] +. 1H NMR (400 MHz, CD3OD) δ8.65 (s, 1H) , 8.35 (d, J = 8.0 Hz, 1H) , 7.93 –7.95 (m, 2H) , 7.73 (d, J = 7.3 Hz, 1H) , 7.63 (d, J =10.4 Hz, 1H) , 7.36 (d, J = 7.3 Hz, 1H) , 6.67 –6.88 (m, 1H) , 6.15 –6.26 (m, 1H) , 5.66 –5.81 (m, 1H) , 3.89 –4.86 (m, 3H) , 3.41 –3.62 (m, 1H) , 3.12 –3.26 (m, 1H) , 2.50 (s, 3H) , 2.24 –2.44 (m, 2H) , 2.02 –2.15 (m, 1H) , 1.76 –1.82 (m, 1H) .
[0158] 3.5.10. Synthesis and Characterization of Compounds 52-54
[0159] Compounds 52-54 were prepared by the method described above in Example 3.5.9. Characterization data for the compounds is provided in Table 4.
[0160] Table 4
[0161] 3.5.11. Synthesis of (R) -1- (3- (4-amino-3- (2- ( (5-methylpyridin-2-yl) amino) benzo [d] thiazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one (Compound 55)
[0162] Step A: 5-bromo-N- (5-methylpyridin-2-yl) benzo [d] thiazol-2-amine
[0163] A mixture of 5-bromo-2-chlorobenzo [d] thiazole (500 mg, 2.01 mmol) , 5-methylpyridin-2-amine (217.57 mg, 2.01 mmol) , NaH (144.86 mg, 6.04 mmol) in THF (10 mL) was stirred at RT for 0.5h under N2 atmosphere. Then the mixture was stirred at 60℃ for 12h under N2 atmosphere. The reaction mixture was diluted with ice water (50 mL) and extracted with EA (3 x 50 mL) . The combined organic phase was washed with brine (50 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE / EA = 1 / 1) to give 5-bromo-N- (5-methylpyridin-2-yl) benzo [d] thiazol-2-amine (200 mg, 31%yield) as a white solid. ESI-MS m / z: 319.9, 321.9 [M+H] +.
[0164] Step B: tert-butyl (R) -3- (4- ( (2, 4-dimethoxybenzyl) amino) -3- (2- ( (5-methylpyridin-2-yl) amino) benzo [d] thiazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate
[0165] A mixture of 5-bromo-N- (5-methylpyridin-2-yl) benzo [d] thiazol-2-amine (200 mg, 0.62 mmol) , B2Pin2 (317.22 mg, 1.25 mmol) , Pd (dppf) Cl2 (91.40 mg, 0.12 mmol) , AcOK (122.59 mg, 1.25 mmol) in dioxane (10 mL) was stirred at 110℃ for 4h under N2 atmosphere. Then tert-butyl (R) -3- (3-bromo-4- ( (2, 4-dimethoxybenzyl) amino) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (150 mg, 0.27 mmol) , K2CO3 (172.64 mg, 1.25 mmol) and H2O (2 mL) was added to mixture and the mixture was continue stirred at 110℃ for 2h under N2 atmosphere. The reaction mixture was diluted with ice water (50 mL) and extracted with EA (3 x 50 mL) . The combined organic phase was washed with brine (50 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE / EA = 1 / 1) to give tert-butyl (R) -3- (4- ( (2, 4-dimethoxybenzyl) amino) -3- (2- ( (5-methylpyridin-2-yl) amino) benzo [d] thiazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (90 mg, 20%yield) as a yellow solid. ESI-MS m / z: 707.2 [M+H] +.
[0166] Step C: (R) -5- (4-amino-1- (piperidin-3-yl) -1H-pyrazolo [4, 3-c] pyridin-3-yl) -N- (5-methylpyridin-2-yl) benzo [d] thiazol-2-amine
[0167] A mixture of tert-butyl (R) -3- (4- ( (2, 4-dimethoxybenzyl) amino) -3- (2- ( (5-methylpyridin-2-yl) amino) benzo [d] thiazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (90 mg, 0.13 mmol) , Et3SiH (29.61 mg, 0.25 mmol) in TFA (3 mL) was stirred at 80℃ for 0.5h. The reaction mixture was concentrated to give (R) -5- (4-amino-1- (piperidin-3-yl) -1H-pyrazolo [4, 3-c] pyridin-3-yl) -N- (5-methylpyridin-2-yl) benzo [d] thiazol-2-amine (58 mg, 100%yield) as a yellow oil. ESI-MS m / z: 457.1 [M+H] +.
[0168] Step D: (R) -1- (3- (4-amino-3- (2- ( (5-methylpyridin-2-yl) amino) benzo [d] thiazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one
[0169] A mixture of (R) -5- (4-amino-1- (piperidin-3-yl) -1H-pyrazolo [4, 3-c] pyridin-3-yl) -N- (5-methylpyridin-2-yl) benzo [d] thiazol-2-amine (58 mg, 0.13 mmol) , prop-2-enoyl chloride (11.50 mg, 0.13 mmol) and TEA (0.04 mL, 0.25 mmol) in DCM (5 mL) was stirred at RT for 0.5h. The reaction mixture was concentrated and then purified by reverse phase chromatography eluted with CH3CN: H2O = 1: 10 ~ 10: 1 to give the title compound (R) -1- (3- (4-amino-3- (2- ( (5-methylpyridin-2-yl) amino) benzo [d] thiazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one (12 mg, 19%yield) as a white solid. ESI-MS m / z: 511.1 [M+H] +. 1H NMR (400 MHz, CD3OD) δ 8.21 (s, 1H) , 7.94 (d, J = 8.0 Hz, 1H) , 7.88 (s, 1H) , 7.75 (d, J = 6.3 Hz, 1H) , 7.58 (d, J = 6.7 Hz, 1H) , 7.48 (d, J = 8.1 Hz, 1H) , 7.07 (d, J = 8.4 Hz, 1H) , 6.94 –6.96 (m, 1H) , 6.65 –6.86 (m, 1H) , 6.13 –6.26 (m, 1H) , 5.65 –5.79 (m, 1H) , 4.32 –4.77 (m, 2H) , 4.09 –4.31 (m, 1H) , 3.36 –3.92 (m, 1H) , 3.09 –3.26 (m, 1H) , 2.24 –2.37 (m, 5H) , 2.04 –2.07 (m, 1H) , 1.73 –1.76 (m, 1H) .
[0170] 3.5.12. Synthesis and Characterization of Compounds 56-60
[0171] Compounds 56-60 were prepared by the method described above in Example 3.5.11. Characterization data for the compounds is provided in Table 5.
[0172] Table 5
[0173] 3.5.13. Synthesis of (R) -1- (3- (4-amino-3- (2- (pyridin-2-yl) benzo [d] thiazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one (Compound 61)
[0174] Step A: 6-bromo-2- (pyridin-2-yl) benzo [d] [1, 3] thiazole
[0175] A mixture of 2-amino-5-bromobenzenethiol (500 mg, 2.45 mmol) , methyl pyridine-2-carboxylate (0.30 mL, 2.45 mmol) , TPP (0.64 mL, 2.45 mmol) and TBAB (789.80 mg, 2.45 mmol) was stirred at 120℃ for 3h. The reaction mixture was cooled to RT, then added MeOH, the white solid was precipitated, the mixture was filtered, the filter cake was dried to give 6-bromo-2- (pyridin-2-yl) benzo [d] [1, 3] thiazole (120 mg, 0.41 mmol, 16.82%) as a white solid. ESI-MS m / z: 290.9 / 292.9 [M+H] +.
[0176] Step B: 2- (pyridin-2-yl) -6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzo [d] thiazole
[0177] To a solution of 6-bromo-2- (pyridin-2-yl) benzo [d] [1, 3] thiazole (120 mg, 0.41 mmol) in dioxane (5 mL) was added 4, 4, 5, 5-tetramethyl-2- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 3, 2-dioxaborolane (156.98 mg, 0.62 mmol) , Pd (dppf) Cl2 (30.16 mg, 0.04 mmol) and KOAc (80.89 mg, 0.82 mmol) , the reaction mixture was degassed with N2 and stirred at 100℃ for 2h. Then the reaction mixture was cooled to RT and used directly in next step without further purification. ESI-MS m / z: 339.7 [M+H] +.
[0178] Step C: tert-butyl (R) -3- (4- ( (2, 4-dimethoxybenzyl) amino) -3- (2- (pyridin-2-yl) benzo [d] thiazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate
[0179] To a solution of 2- (pyridin-2-yl) -6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzo [d] [1, 3] thiazole (120 mg, 0.35 mmol) in dioxane (5 mL) and H2O (1 mL) was added tert-butyl (R) -3- (3-bromo-4- ( (2, 4-dimethoxybenzyl) amino) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (193.88 mg, 0.35 mmol) , Pd (dppf) Cl2 (25.96 mg, 0.04 mmol) and K2CO3 (147.10 mg, 1.06 mmol) , the reaction mixture was degassed with N2 and stirred at 100℃ for 2h. Then the reaction mixture was concentrated, the residue was purified by chromatography on silica gel (0-90%, EA in PE) to afford tert-butyl (R) -3- (4- ( (2, 4-dimethoxybenzyl) amino) -3- (2- (pyridin-2-yl) benzo [d] thiazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (180 mg, 0.27 mmol, 74.85%) as a yellow oil. ESI-MS m / z: 678.1 [M+H] +.
[0180] Step D: (R) -1- (piperidin-3-yl) -3- (2- (pyridin-2-yl) benzo [d] thiazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-4-amine
[0181] To a solution of tert-butyl (R) -3- (4- ( (2, 4-dimethoxybenzyl) amino) -3- (2- (pyridin-2-yl) benzo [d] thiazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidine-1-carboxylate (180 mg, 0.27 mmol) in TFA (3 mL) was added Et3SiH (62.79 mg, 0.54 mmol) at RT and the reaction mixture was stirred at 80℃ for 10 min. The reaction mixture was concentrated to give (R) -1- (piperidin-3-yl) -3- (2- (pyridin-2-yl) benzo [d] thiazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-4-amine (110 mg) as a yellow oil, which was used directly in next step without further purification. ESI-MS m / z: 428.1 [M+H] +.
[0182] Step E: (R) -1- (3- (4-amino-3- (2- (pyridin-2-yl) benzo [d] thiazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one
[0183] To a solution of (R) -1- (piperidin-3-yl) -3- (2- (pyridin-2-yl) benzo [d] thiazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-4-amine (110 mg, 0.26 mmol) in THF (3 mL) and H2O (0.5 mL) was added NaHCO3 (43.69 mg, 0.52 mmol) and prop-2-enoyl chloride (23.29 mg, 0.26 mmol) at 0℃and the reaction mixture was stirred at 0℃ for 10 min. The reaction mixture was quenched with H2O, and concentrated. The residue was purified by Pre-HPLC (0-40%, MeCN in H2O, 0.05%TFA) to afford (R) -1- (3- (4-amino-3- (2- (pyridin-2-yl) benzo [d] thiazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one (25.72 mg, 0.05 mmol, 20.74%) as a white solid. ESI-MS m / z: 482.0 [M+H] +. 1H NMR (400 MHz, DMSO-d6) δ 12.92 (s, 1H) , 8.77 (dt, J = 4.8, 1.3 Hz, 1H) , 8.48 (s, 1H) , 8.42 –8.37 (m, 1H) , 8.28 (d, J = 8.5 Hz, 1H) , 8.11 –8.06 (m, 1H) , 8.01 (s, 1H) , 7.85 (dd, J = 13.8, 8.1 Hz, 2H) , 7.64 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H) , 7.47 (dd, J = 10.7, 7.2 Hz, 1H) , 6.84 (ddd, J = 52.3, 16.6, 10.5 Hz, 1H) , 6.22 –6.04 (m, 1H) , 5.79 –5.58 (m, 1H) , 4.89 (d, J = 38.5 Hz, 1H) , 4.60 –4.07 (m, 2H) , 3.37 –3.17 (m, 2H) , 2.19 (s, 2H) , 1.93 (d, J = 11.8 Hz, 1H) , 1.64 (s, 1H) .
[0184] 3.5.14. Synthesis and Characterization of (R) -1- (3- (4-amino-3- (2- (5-methylpyridin-2-yl) benzo [d] thiazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one (Compound 62)
[0185] Compound 62 was prepared according to the method described above in Example 3.5.13. ESI-MS m / z: 496.3 [M+H] +. 1H NMR (400 MHz, CDCl3) δ 8.54 (s, 1H) , 8.33 –8.27 (m, 2H) , 8.21 (d, J = 8.4 Hz, 1H) , 7.81 (d, J = 8.5 Hz, 2H) , 7.70 (d, J = 8.5 Hz, 1H) , 6.87 –6.51 (m, 1H) , 6.39 –6.35 (m, 1H) , 5.77 –5.73 (m, 1H) , 5.56 –5.34 (m, 1H) , 4.95 –4.93 (m, 0.5H) , 4.45 –4.41 (m, 1H) , 4.16 –4.00 (m, 1H) , 3.79 –3.74 (m, 0.5H) , 3.24 –3.19 (m, 2H) , 2.45 (s, 3H) , 2.34 –2.30 (m, 1H) , 2.04 –2.01 (m, 1H) , 1.78 –1.76 (m, 1H) , 1.29 –1.27 (m, 1H) .
[0186] 3.5.15. Synthesis of (R) -1- (3- (4-amino-3- (1-methyl-2- (5-methylpyridin-2-yl) -1H-benzo [d] imidazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one (Compound 63)
[0187] Step A: 5-bromo-1-methyl-2- (5-methylpyridin-2-yl) -1H-benzo [d] imidazole
[0188] A mixture of 5-methylpicolinaldehyde (360 mg, 2.97 mmol) , 4-bromo-N1-methylbenzene-1, 2-diamine (597.53 mg, 2.97 mmol) and S (95.10 mg, 2.97 mmol) in DMA (10 mL) was stirred at 45℃ for 2h. The reaction mixture was filtered and the filtrate was purified by reverse phase chromatography eluted with CH3CN: H2O = 1: 10 ~ 10: 1 to give the title compound 5-bromo-1-methyl-2- (5-methylpyridin-2-yl) -1H-benzo [d] imidazole (140 mg, 16%yield) as a yield solid. ESI-MS m / z: 302.0, 304.0 [M+H] +.
[0189] Step B: tert-butyl (R) -3- (4-amino-3- (1-methyl-2- (5-methylpyridin-2-yl) -1H-benzo [d] imidazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidine-1-carboxylate
[0190] A mixture of 5-bromo-1-methyl-2- (5-methylpyridin-2-yl) -1H-benzo [d] imidazole (140 mg, 0.46 mmol) , B2Pin2 (235.30 mg, 0.93 mmol) , Pd (dppf) Cl2 (67.80 mg, 0.09 mmol) , KOAc (90.94 mg, 0.93 mmol) in dioxane (5 mL) was stirred at 110℃ for 1h under N2 atmosphere. Then tert-butyl (R) -3- (4-amino-3-bromo-1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidine-1-carboxylate (120 mg, 0.30 mmol) , K2CO3 (128.06 mg, 0.93 mmol) and H2O (1 mL) was added to mixture and the mixture was continue stirred at 110℃ for 2h under N2 atmosphere. The reaction mixture was diluted with ice water (20 mL) and extracted with EA (3 x 20 mL) . The combined organic phase was washed with brine (20 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE / EA = 1 / 1) to give tert-butyl (R) -3- (4-amino-3- (1-methyl-2- (5-methylpyridin-2-yl) -1H-benzo [d] imidazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidine-1-carboxylate (130 mg, 52%yield) as a yellow solid. ESI-MS m / z: 540.3 [M+H] +.
[0191] Step C: (R) -3- (1-methyl-2- (5-methylpyridin-2-yl) -1H-benzo [d] imidazol-5-yl) -1- (piperidin-3-yl) -1H-pyrazolo [3, 4-d] pyrimidin-4-amine
[0192] A mixture of tert-butyl (R) -3- (4-amino-3- (1-methyl-2- (5-methylpyridin-2-yl) -1H-benzo [d] imidazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidine-1-carboxylate (130 mg, 0.24 mmol) in TFA (3 mL) / DCM (3 mL) was stirred at 30℃ for 0.5h. The reaction mixture was concentrated to give (R) -3- (1-methyl-2- (5-methylpyridin-2-yl) -1H-benzo [d] imidazol-5-yl) -1- (piperidin-3-yl) -1H-pyrazolo [3, 4-d] pyrimidin-4-amine (105 mg, 99%yield) as a yellow oil. ESI-MS m / z: 440.2 [M+H] +.
[0193] Step D: (R) -1- (3- (4-amino-3- (1-methyl-2- (5-methylpyridin-2-yl) -1H-benzo [d] imidazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one
[0194] To a mixture of (R) -3- (1-methyl-2- (5-methylpyridin-2-yl) -1H-benzo [d] imidazol-5-yl) -1- (piperidin-3-yl) -1H-pyrazolo [3, 4-d] pyrimidin-4-amine (105 mg, 0.24 mmol) and saturated NaHCO3 aq. (1.78 mL, 1.91 mmol) in THF (5 mL) was added dropwise prop-2-enoyl chloride (21.62 mg, 0.24 mmol) at ice bath and then the mixture was stirred at RT for 5 minutes. The reaction mixture was filtered and the filtrate was purified by reverse phase chromatography eluted with CH3CN: H2O = 1: 10 ~ 10: 1 to give the title compound (R) -1- (3- (4-amino-3- (1-methyl-2- (5-methylpyridin-2-yl) -1H-benzo [d] imidazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one (15 mg, 13%yield) as a white solid. ESI-MS m / z: 494.2 [M+H] +.
[0195] 3.5.16. Synthesis of (R) -1- (3- (8-amino-1- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) imidazo [1, 5-a] pyrazin-3-yl) piperidin-1-yl) prop-2-en-1-one (Compound 80)
[0196] Step A: benzyl (R) -3- ( ( (3-chloropyrazin-2-yl) methyl) carbamoyl) piperidine-1-carboxylate
[0197] A mixture of (3-chloropyrazin-2-yl) methanamine (4800 mg, 33.43 mmol) , (R) -1- ( (benzyloxy) carbonyl) piperidine-3-carboxylic acid (8792.92 mg, 33.43 mmol) , HATU (19068.94 mg, 50.15 mmol) and DIEA (6469.32 mg, 50.15 mmol) in DMF (20 mL) was stirred at 30℃ for 1h. The reaction mixture was diluted with ice water (250 mL) and extracted with EA (3 x 200 mL) . The combined organic phase was washed with brine (250 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE / EA = 1 / 1) to give benzyl (R) -3- ( ( (3-chloropyrazin-2-yl) methyl) carbamoyl) piperidine-1-carboxylate (8000 mg, 62%yield) as a yellow solid. ESI-MS m / z: 389.1 [M+H] +.
[0198] Step B: benzyl (R) -3- (8-chloroimidazo [1, 5-a] pyrazin-3-yl) piperidine-1-carboxylate
[0199] To a mixture of benzyl (R) -3- ( ( (3-chloropyrazin-2-yl) methyl) carbamoyl) piperidine-1-carboxylate (8000 mg, 20.57 mmol) and DMF (1.65 mL, 20.57 mmol) in CH3CN (50 mL) was added POCl3 (3154.33 mg, 20.57 mmol) at 0℃ under N2 atmosphere. Then the reaction mixture was refluxed at 65℃ for 2h. The reaction mixture was poured carefully in ammonium hydroxide 25%in water (50ml) / crushed ice (50 ml) to give a yellow suspension (pH ~8-9) which was stirred for 15 min until no ice was present in the suspension. Ethyl acetate was added, layers were separated and the aqueous layer was extracted with ethyl acetate (3x100 ml) . The combined organic phase was washed with brine (50 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE / EA = 1 / 1) to give benzyl (R) -3- (8-chloroimidazo [1, 5-a] pyrazin-3-yl) piperidine-1-carboxylate (6000 mg, 79%yield) as a yellow oil. ESI-MS m / z: 371.1 [M+H] +
[0200] Step C: benzyl (R) -3- (1-bromo-8-chloroimidazo [1, 5-a] pyrazin-3-yl) piperidine-1-carboxylate
[0201] To a mixture of benzyl (R) -3- (8-chloroimidazo [1, 5-a] pyrazin-3-yl) piperidine-1-carboxylate (6000 mg, 17.81 mmol) in DMF (20 mL) was added NBS (3167.77 mg, 17.80 mmol) at 0℃ and then the mixture was stirred at 30℃ for 1h. The reaction mixture was diluted with ice water (50 mL) and extracted with EA (3 x 50 mL) . The combined organic phase was washed with brine (50 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE / EA = 1 / 1) to give benzyl (R) -3- (1-bromo-8-chloroimidazo [1, 5-a] pyrazin-3-yl) piperidine-1-carboxylate (5500 mg, 76%yield) as a yellow solid. ESI-MS m / z: 449.0, 451.0 [M+H] +
[0202] Step D: benzyl (R) -3- (8-amino-1-bromoimidazo [1, 5-a] pyrazin-3-yl) piperidine-1-carboxylate
[0203] A mixture of benzyl (R) -3- (1-bromo-8-chloroimidazo [1, 5-a] pyrazin-3-yl) piperidine-1-carboxylate (5500 mg, 12.23 mmol) in NH4OH (10 mL) / Isopropanol (20 mL) was stirred at 110℃ for 6h. The reaction mixture was concentrated. The residue was purified by flash chromatography on silica gel (PE / EA = 1 / 1) to give benzyl (R) -3- (8-amino-1-bromoimidazo [1, 5-a] pyrazin-3-yl) piperidine-1-carboxylate (3500 mg, 67%yield) as a yellow solid. ESI-MS m / z: 430.1, 432.1 [M+H] +
[0204] Step E: benzyl (R) -3- (8-amino-1- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) imidazo [1, 5-a] pyrazin-3-yl) piperidine-1-carboxylate
[0205] A mixture of 6-bromo-2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazole (178.43 mg, 0.58 mmol) , B2Pin2 (295.07 mg, 1.16 mmol) , Pd (dppf) Cl2 (85.02 mg, 0.12 mmol) , KOAc (114.03 mg, 1.16 mmol) and K2CO3 (160.58 mg, 1.16 mmol) in dioxane (3 mL) was stirred at 110℃ for 1.5h under N2 atmosphere. Then benzyl (R) -3- (8-amino-1-bromoimidazo [1, 5-a] pyrazin-3-yl) piperidine-1-carboxylate (250 mg, 0.58 mmol) and H2O (1 mL) was added to mixture and the mixture was continue stirred at 110℃ for 2h under N2 atmosphere. The reaction mixture was diluted with ice water (20 mL) and extracted with EA (3 x 20 mL) . The combined organic phase was washed with brine (20 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE / EA = 1 / 1) to give benzyl (R) -3- (8-amino-1- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) imidazo [1, 5-a] pyrazin-3-yl) piperidine-1-carboxylate (140 mg, 42%yield) as a yellow solid. ESI-MS m / z: 578.2 [M+H] +.
[0206] Step F: (R) -1- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -3- (piperidin-3-yl) imidazo [1, 5-a] pyrazin-8-amine
[0207] A mixture of benzyl (R) -3- (8-amino-1- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) imidazo [1, 5-a] pyrazin-3-yl) piperidine-1-carboxylate (140 mg, 0.24 mmol) in TFA (2 mL) / CF3SO3H (0.5 mL) was stirred at 30℃ for 5 minutes. The reaction mixture was concentrated and the pH was adjusted to 8 with saturated aqueous NaHCO3. The resulting solution was extracted with DCM (3 x 30 mL) . The combined organic phase was washed with brine (10 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography on silica gel (DCM / MeOH = 10 / 1) to give (R) -1- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -3- (piperidin-3-yl) imidazo [1, 5-a] pyrazin-8-amine (60 mg, 56%yield) as a yellow solid. ESI-MS m / z: 444.2 [M+H] +.
[0208] Step G: (R) -1- (3- (8-amino-1- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) imidazo [1, 5-a] pyrazin-3-yl) piperidin-1-yl) prop-2-en-1-one
[0209] To a mixture of (R) -1- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -3- (piperidin-3-yl) imidazo [1, 5-a] pyrazin-8-amine (60 mg, 0.14 mmol) and saturated NaHCO3 (1.01mL, 1.08 mmol) in THF (2 mL) was added dropwise prop-2-enoyl chloride (12.25 mg, 0.14 mmol) at ice bath and then the mixture was stirred at RT for 5min. The reaction mixture was filtered and the filtrate was purified by reverse phase chromatography eluted with CH3CN: H2O = 1: 10 ~ 10: 1 to give the title compound (R) -1- (3- (8-amino-1- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) imidazo [1, 5-a] pyrazin-3-yl) piperidin-1-yl) prop-2-en-1-one (12 mg, 18%yield) as a white solid. ESI-MS m / z: 498.2 [M+H] +.
[0210] 3.5.17. Synthesis and Characterization of Compounds 75-79 and 81-82
[0211] Compounds 75-79 and 81-82 were prepared by the method described above in Example 3.5.16. Characterization data for the compounds is provided in Table 6.
[0212] Table 6
[0213] 3.5.18. ITK and BTK Biochemical Activity Assay
[0214] The ability of compounds to inhibit ITK or BTK in vitro was assessed by monitoring the amount of phosphorylation of fluorescein-labeled peptide substrates in the presence of active enzyme, ATP, and the compound. The half inhibition concentration (IC50) was measured in 384-well plates as described below.
[0215] Test compound was prepared by serial dilution. The compound was dissolved in 100%DMSO (Sigma) to a concentration of 10 μM, then diluted three-fold in a serial gradient manner with DMSO to the concentrations specified. 10 nL of the compound solution was dispensed into a 384-well white assay plate and 10 nL of DMSO was added to the positive control well. The kinase used in the assay (ITK or BTK, Carna Bioscience) was diluted with the assay buffer, 5 μL of the resulting kinase solution was added into the well, the final concentration was 5 nM for ITK and 15 nM for BTK. 5 μL assay buffer was added to the negative control well. The plate was incubated at 25℃ for 30 minutes, after which 3 μM FL-Peptide 27 (PerkinElmer) was diluted with the assay buffer and together with 20 μM ATP was added into each well to obtain a final concentration of 1.5 μM compound and 10 μM for ATP for the ITK assay; 3 μM FL-Peptide 2 (PerkinElmer) diluted with the assay buffer together with 200 μM ATP was added into wells to obtain a final concentration of 1.5 μM compound and 100 μM ATP for BTK assays. To each well, 5 μL of this peptide / ATP-solution was added to start the reaction.
[0216] The plate was incubated at 25℃ for 120 minutes, followed by the addition of 10 μL of ADP-GloTM reagent (Promega) to each well. After incubation at 25℃ for 60 min, 20 μL of ADP-GloTM detection reagent was added. The plate was then incubated at 25℃ for 45 minutes. The chemiluminescence of the sample from each well was detected using an the EnSightTM plate reader. The remaining activity (%) was calculated using the readout (RD) following the equation as: Remaining activity (%) =100-100 x (RDPC-RDsample) / (RDPC-RDNC) , where the well that was treated with DMSO served as positive control (PC) and the one with assay buffer as negative control (NC) . IC50 values were calculated using the analysis software (equation 201) .
[0217] 3.5.19. Cellular ITK Inhibition Assay
[0218] ITK is an important downstream mediator of TCR signaling. Inhibition of ITK will inhibit IL-2 production in Jurkat cells. The cellular Jurkat assay measures the ability of test compounds to block IL-2 production mediated by ITK inhibition. In this assay, Jurkat cells (cultured in X-vivo-15 medium, Lonza, 04-418Q) are stimulated with anti-CD3 / CD28 antibodies in the presence of test compound and IL-2 secreted is measured using an ELISA detection method. Briefly, Jurkat cells (5×104) were added in anti-CD3 (OKT3, 10 μg / mL, 120 μL / well, Invitrogen, 16-0037-85) pre-coated 96-well plates and cultured in 37℃ CO2 incubator, with reference compound and anti-CD28 antibody (10 μg / mL, CD28.2, Invitrogen, 16-0289-85) and test compounds for 16-24h. Test and reference compounds were serially diluted (3×dilution, final concentration starting from 10 μM, total 10 dilution points, final DMSO concentration was 0.1%) , with culture medium before adding to wells. supernatants were collected and the quantities of the secreted IL-2 were determined using the human IL-2 ELISA kit (Sino Biological, KIT11848) according to the manufacturer’s protocol. Briefly, IL-2 standards and samples (100 μL) were added to each well of the plate, followed by addition of the antibody reagent (100 μL) from the kit and the plate was incubated for 1h at room temperature. The plate was then washed 3 times and 100 μL of detection solution from the kit was added. After 20 minutes of incubation at room temperature, the plate was washed 3 times. Finally, the stop solution (100 μL) from the kit was added and in 10 minutes the absorbance of each well was read at 450nm using a Varioskan LUX plate reader (Thermo Fisher Scientific) . GraphPad Prism 9 was used for non-linear regression curve-fitting and IC50 calculations.
[0219] 3.5.20. Cellular BTK Inhibition Assay
[0220] BTK is a critical downstream mediator in the BCR signaling pathway and its inhibition will attenuate B cell activation as demonstrated by attenuation of CD69 expression. In this assay, cryopreserved human peripheral blood mononuclear cells (PBMCs, Milestone Bio) were cultured in RPMI 1640 medium supplemented with 10%fetal bovine serum and seeded in 96-well plates at 2.0×105 cells per well and treated with the test and reference compounds at 37℃ in a CO2 incubator for 1 hour. Compounds were serially diluted (3×dilution, final concentration starting from 10 μM, total 10 dilution points, final DMSO concentration was 0.05%) with culture medium before adding to wells. After 1 hour treatment, cells were stimulated with goat anti-human IgM (SouthernBiotech, 2022-01, final concentration 10 μg / mL) at 37℃ in a CO2 incubator for 16-24 hours. Cells were then stained with anti-CD20-FITC (BD, 555622) and anti-CD69-PE (BD, 555531) antibodies following standard protocol. The percentages of CD69+ cells in the CD20+ population were analyzed using Cytoflex (Beckman Coulter) . GraphPad Prism 9 was used for non-linear regression curve-fitting and IC50 calculation.
[0221] 3.5.21. Kinase Inhibition
[0222] The IC50 values for ITK and BTK inhibition were determined for various compound of the invention. Biochemical assay data were obtained as described above in Example 3.5.18. Cellular assay data were obtained as described in Examples 3.5.19 and 3.5.20.
[0223] Results are presented in Table 7, wherein different symbols are used to reflect IC50 values obtained using the different assays: for the biochemical assay data, *means IC50 > 100 nM, **means IC50 ≤ 100 nM, ***means IC50 ≤ 50 nM, ****means IC50 ≤ 25 nM; and “--” means data was not obtained; for the ITK cell-based assay data, #means IC50 > 1000 nM, ##means IC50 ≤ 1000 nM, ###means IC50 ≤ 300 nM, ####means IC50 ≤ 100 nM; and “--” means data was not obtained; and for the BTK cell-based assay data, + means IC50 > 100 nM, ++ means IC50 ≤ 100 nM, +++ means IC50 ≤ 50 nM, ++++ means IC50 ≤ 10 nM; and “--” means data was not obtained.
[0224] Table 7
[0225] As these data clearly show, this invention provides compounds that are potent inhibitors of ITK and BTK.
[0226] ~
[0227] All publications (e.g., patents and patent applications) cited above are incorporated herein by reference in their entireties.
Claims
1.A compound of formula I or a pharmaceutically acceptable salt thereof, wherein:X1 is N, NRX1, S, or O;X2 is N, NRX2, S, or O;Z1 is N or CH;Z2 is N or CH;Z3 is N or C if at least one of Z1 and Z2 is CH; Z3 is C if both Z1 and Z2 are N;L is a bond or -NH-;RX1 is H or C1-3 alkyl;RX2 is H or C1-3 alkyl;A1 is 4-9 membered heterocycloalkyl;A2 is aryl or 5-6 membered heteroaryl;R1 is H or optionally substituted C2-4 alkenyl or C2-4 alkynyl, which optional substitution is with at least one (e.g., one, two, or three) R1A;each R1A is independently cyano, halo, hydroxy, C1-6 alkyl, C1-6 alkoxy, -CH2- (4- (oxetan-3-yl) piperazin) , -CHCH3- (4- (oxetan-3-yl) piperazin) , or -C (CH3) 2- (4- (oxetan-3-yl) piperazin) ;each R2 is independently cyano, halo, NR2AR2B, or optionally substituted C2-4 alkynyl, C2-4 alkenyl, C1-6 alkyl, C3-6 cycloalkyl, C3-6 heterocycloalkyl, or C1-6 alkoxy, which optional substitution is with at least one (e.g., one, two, or three) of halo or C1-3 alkyl;R2A is H, C1-3 alkyl, or oxetan;R2B is H or C1-3 alkyl;each R3 is independently halo;each R4 is independently halo, cyano, or optionally substituted C1-3 alkyl or C3-6 cycloalkyl, which optional substitution is with at least one (e.g., one, two, or three) halo;n is 0-3;m is 0-2; andp is 0-2.2.The compound of claim 1, which is of formula II wherein Y is CH2 or O.3.The compound of claim 1, which is of formula III wherein Z4 is N or CH.4.The compound of claim 1 or 3, wherein A1 is pyrrolidine or piperidine.5.The compound of claim 1 or 2, wherein A2 is imidazolyl, isoxazolyl, oxazolyl, phenyl, pyrazolyl, pyridyl, or thiazolyl.6.The compound of claim 1, which is of formula IV wherein Y is CH2 or O.7.The compound of claim 1, which is of formula V wherein Y is CH2 or O.8.The compound of any of claims 2, 6, or 7, wherein Y is CH2.9.The compound of any of claims 3, 6, or 7, wherein Z4 is N.10.The compound of any of claims 1-9, wherein X1 is N.11.The compound of any of claims 1-10, wherein X2 is O or S.12.The compound of claim 11, wherein X1 is N and X2 is O.13.The compound of any of claims 1-12, wherein m is 0.14.The compound of any of claims 1-13, wherein n is 1.15.The compound of any of claims 1-13, wherein n is 2.16.The compound of claim 14 or 15, wherein each R2 is independently halo or optionally substituted C1-6 alkyl (e.g., methyl, C1-6 alkyl substituted with one or more halo) .17.The compound of any of claims 1-16, wherein p is 0.18.The compound of any of claims 1-16, wherein p is 1.19.The compound of claim 18, wherein R4 is optionally substituted C1-3 alkyl (e.g., methyl) .20.The compound of any of claims 1-19, wherein L is a bond.21.The compound of any of claims 1-20, wherein R1 is optionally substituted C2-4 alkenyl.22.The compound of claim 21, wherein R1 is -CH=CH2.23.The compound of claim 21, wherein R1 is -CH=CH2 substituted with halo.24.The compound of claim 21, wherein R1 is -CH=CH2 substituted with cyano.25.The compound of claim 21, wherein R1 is -CH=CH2 substituted with -CH2- (4-(oxetan-3-yl) piperazin) , -CHCH3- (4- (oxetan-3-yl) piperazin) , or -C (CH3) 2- (4- (oxetan-3-yl)piperazin) .26.The compound of any of claims 1-25, wherein the stereochemistry at the stereocenter labeled with an asterisk (*) is (R) .27.The compound of claim 1, which is selected from the group consisting of:(R) -1- (3- (4-amino-3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5- (trifluoromethyl) pyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c]pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-fluoropyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c]pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-chloropyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c]pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (6-fluoropyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c]pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5, 6-dichloropyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c]pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (6-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c]pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-ethyl-6-fluoropyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (4-isopropylphenyl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c]pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-isopropylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c]pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (pyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl)piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5- (trifluoromethyl) pyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-fluoropyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c]pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c]pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-ethyl-6-fluoropyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (4-isopropylphenyl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c]pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-isopropylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c]pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (pyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl)piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d]pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-ethyl-6-fluoropyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (pyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-isopropylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d]pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5, 6-dimethylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d]pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (2-methyloxazol-4-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d]pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-ethylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d]pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-methylisoxazol-3-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d]pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (1-methyl-1H-pyrazol-3-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5- (azetidin-1-yl) pyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-fluoro-6-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (6-fluoro-5- (prop-1-en-1-yl) pyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-ethyl-6-fluoropyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (pyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-isopropylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d]pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5, 6-dimethylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d]pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d]pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-ethylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d]pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-fluoro-6-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (5-chloro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (5-chloro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (7-fluoro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (6-chloro-5-methylpyridin-2-yl) -7-fluorobenzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (7-fluoro-2- (5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (6-chloro-5-methylpyridin-2-yl) -7-fluorobenzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- ( (5-methylpyridin-2-yl) amino) benzo [d] thiazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- ( (5-isopropylpyridin-2-yl) amino) benzo [d] thiazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- ( (6-fluoropyridin-2-yl) amino) benzo [d] thiazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- ( (5-methylpyridin-2-yl) amino) benzo [d] thiazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- ( (5-isopropylpyridin-2-yl) amino) benzo [d] thiazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- ( (6-fluoropyridin-2-yl) amino) benzo [d] thiazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (pyridin-2-yl) benzo [d] thiazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl)piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-methylpyridin-2-yl) benzo [d] thiazol-6-yl) -1H-pyrazolo [4, 3-c]pyridin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (1-methyl-2- (5-methylpyridin-2-yl) -1H-benzo [d] imidazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R, E) -1- (3- (4-amino-3- (2- (6-chloro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) -4- (4- (oxetan-3-yl) piperazin-1-yl) but-2-en-1-one;(R, E) -1- (3- (4-amino-3- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) -4- (4- (oxetan-3-yl) piperazin-1-yl) but-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5- (methyl (oxetan-3-yl) amino) pyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) -2-fluoroprop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) but-2-yn-1-one;(R, E) -2- (3- (4-amino-3- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidine-1-carbonyl) -4-methyl-4- (4- (oxetan-3-yl) piperazin-1-yl)pent-2-enenitrile;(R) -1- (3- (4-amino-3- (2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c]pyridin-1-yl) piperidin-1-yl) -2-fluoroprop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c]pyridin-1-yl) piperidin-1-yl) -2-fluoroprop-2-en-1-one;(R) -1- (3- (4-amino-3- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) piperidin-1-yl) -2-fluoroprop-2-en-1-one;1- ( (2S, 5R) -5- (4-amino-3- (2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) -2-methylpiperidin-1-yl) prop-2-en-1-one;1- ( (2R, 5R) -5- (4-amino-3- (2- (5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) -1H-pyrazolo [4, 3-c] pyridin-1-yl) -2-methylpiperidin-1-yl) prop-2-en-1-one;(R) -1- (2- (8-amino-1- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) imidazo [1, 5-a]pyrazin-3-yl) morpholino) prop-2-en-1-one;(R) -1- (2- (8-amino-1- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) imidazo [1, 5-a]pyrazin-3-yl) morpholino) prop-2-en-1-one;(R, E) -1- (3- (8-amino-1- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-5-yl)imidazo [1, 5-a] pyrazin-3-yl) piperidin-1-yl) -4- (4- (oxetan-3-yl) piperazin-1-yl) but-2-en-1-one;(R) -1- (3- (8-amino-1- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-5-yl) imidazo [1, 5-a]pyrazin-3-yl) piperidin-1-yl) prop-2-en-1-one(R) -1- (3- (8-amino-1- (2- (5-fluoro-6-methylpyridin-2-yl) benzo [d] oxazol-5-yl) imidazo [1, 5-a]pyrazin-3-yl) piperidin-1-yl) prop-2-en-1-one;(R) -1- (3- (8-amino-1- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) imidazo [1, 5-a]pyrazin-3-yl) piperidin-1-yl) prop-2-en-1-one;(S) -1- (2- (8-amino-1- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) imidazo [1, 5-a]pyrazin-3-yl) pyrrolidin-1-yl) but-2-yn-1-one;(S) -1- (2- (8-amino-1- (2- (6-fluoro-5-methylpyridin-2-yl) benzo [d] oxazol-6-yl) imidazo [1, 5-a]pyrazin-3-yl) pyrrolidin-1-yl) prop-2-en-1-one; andpharmaceutically acceptable salts thereof.28.A formulation comprising a pharmaceutically acceptable excipient and a compound of any of claims 1-27.29.A single unit dosage form comprising the formulation of claim 28.30.A method of inhibiting ITK, which comprises contacting a compound of any of claims 1-27 with ITK.31.A method of inhibiting BTK, which comprises contacting a compound of any of claims 1-27 with BTK.32.A method of treating or managing a disease or condition, which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of any of claims 1-27 or a pharmaceutical composition of claim 28 or 29, wherein the disease or condition is associated with ITK activity.33.A compound of any of claims 1-27 or a pharmaceutical composition of claim 28 or 29 for use in the treatment or management of a disease or condition associated with ITK activity.34.A method of treating or managing a disease or condition, which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of any of claims 1-27 or a pharmaceutical composition of claim 28 or 29, wherein the disease or condition is associated with BTK activity.35.A method of treating or managing an autoimmune or inflammatory disease or condition, which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of any of claims 1-27 or a pharmaceutical composition of claim 28 or 29.36.A compound of any of claims 1-27 or a pharmaceutical composition of claim 28 or 29 for use in treating or managing an autoimmune or inflammatory disease or condition.37.The method of claim 35 or the use of claim 36, wherein the autoimmune or inflammatory disease or condition is acne vulgaris, Addition’s disease, alopecia areata, ankylosing spondylitis, asthma, atherosclerosis, atopic dermatitis, autoimmune hemolytic anemia, Behcet’s disease, celiac disease, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, Crohn’s disease, diabetes mellitus type I, eosinophilic esophagitis, erythematosus, Goodpasture syndrome, graft-versus-host disease, Graves’ disease, Hashimoto’s encephalopathy, Hashimoto's thyroiditis, idiopathic thrombocytopenic purpura, IgA nephropathy, ischemia reperfusion injury, juvenile onset diabetes, lupus nephritis, multiple sclerosis, neuromyelitis optica spectrum disease (NMOSD) , oligodendrocyte glycoprotein (MOG) immunoglobulin G-associated disease (MOGAD) , pemphigus primary membranous nephropathy, prurigo nodularis, psoriasis, psoriatic arthritis, reperfusion injury, rheumatoid arthritis, scleroderma, syndrome, stroke, systemic lupus, ulcerative colitis, vasculitis, or vitiligo.38.A method of treating or managing cancer, which comprises administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound of any of claims 1-27 or a pharmaceutical composition of claim 28 or 29.39.A compound of any of claims 1-27 or a pharmaceutical composition of claim 28 or 29 for use in treating or managing cancer.40.The method of claim 38 or the use of claim 39, wherein the cancer is bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck squamous cell carcinoma, hematologic cancer, Hodgkin lymphoma, lung cancer, Merkel-cell carcinoma, melanoma, mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small cell lung cancer, transitional cell carcinoma, or urothelial cancer.41.The method or use of claim 40, wherein the hematologic cancer is a B-cell malignancy.42.The method or use of claim 41, wherein the B-cell malignancy is chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, or macroglobulinemia.
